AI business Recursion Pharmaceuticals has narrowed its drug development pipeline, ending or pausing five programmes as it seeks to reduce costs and reprioritise resources following a merger with ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes ...

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported less-than ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported less-than ...

The company published its latest quarterly earnings report this morning. It continues to draw limited revenue, while its costs are growing notably. Recursion Pharmaceuticals (NASDAQ: RXRX) didn't ...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Monday reported a loss of $202.5 million in its first quarter. On a per-share basis, the Salt Lake City ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) are tumbling on Tuesday. The stock lost 10.3% as of 2:50 p.m. ET and was down by as much as 11.8% earlier in the day. The move comes as the S&P ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) fell this week. The stock lost 24% as of market close on Friday. The move comes as the S&P 500 and Nasdaq Composite both slipped slightly.

Yormark doesn’t wield Sankey’s influence or sit atop a behemoth like the SEC, but in terms of what he’s meant to his conference – how decisively he’s altered its trajectory – no one in ...